Abstract:Recent advances in ″omics″ technologies allow for the identification of an increasing number of individuals with diseases caused by nano-rare mutations. These difficult-to-diagnose individuals are uniquely disadvantaged and pose significant challenges to healthcare systems and society. Despite having diseases caused by actionable single gene mutations, in many cases, there is no commercial path for treatments for such small patient populations. Since antisense oligonucleotide (ASO) technology has proven to be suited to address the needs of a portion of these patients, the n-Lorem Foundation is establishing an industrialized approach that couples detailed genotypic and phenotypic data to the immediate potential for ASO therapy. In this manuscript we have leveraged our experience in assessing the causality of nano-rare genetic variants and associated proximal molecular pathological events to attempt a correlation between detailed genetic data with patient specific phenotypic observations in 173 nano-rare individuals from diverse age groups evaluated for experimental ASO therapy. We found that the time required to achieve a molecular diagnosis varies from 1 month to 36 years, with the mean and median times from symptom onset to diagnosis estimated to be 4.32 years and 2 years, respectively. Amongst submitted cases there is a significant bias toward neurological diseases, with diverse genes and functional families involved and a marked preponderance of mutations in ion channel genes. The variability in phenotypic expression associated with nano-rare variants in genes such as GNAO1, H3F3A, GBE1, UBTF, or PACS1 clearly supports previous observations that phenotypes associated with same variants in the same gene can vary. We also observe that different, but functionally equivalent variants can result in both similar (e.g., TARDBP) and different phenotypes (e.g., GNAO1). Despite the relatively small size of the patient population investigated, this first compilation of its kind allows a variety of insights into the genotype and phenotype relationships in nano-rare conditions. Moreover, we show that our unique patient population presents a remarkable opportunity to apply ″modern omics″ approaches to begin to understand the various homeostatic, compensatory, and secondary effects of these genetic variants on the networks that result in expression of their unique phenotypes. To provide a more detailed description of the processes involved to provide a personalized antisense medicine, we have included nonclinical and clincal data on four exemplary patients who display disease in three different organs, the CNS, the eye and the kidney and are treated with ASOs of different designs. In contrast to traditional drug development, each patient presents unique genomic, ASO design, clinical treatment and management and evaluation challenges.

What problem does this paper attempt to address?

The main problem that this paper attempts to solve is to provide effective experimental antisense oligonucleotide (ASO) treatment for patients with extremely rare pathogenic mutations (nano - rare mutations). The diseases of these patients are caused by single - gene mutations with a known global prevalence of less than 30 cases, resulting in multiple challenges such as difficult diagnosis, limited treatment options, and insufficient medical system and social support. ### Specific Problems and Solutions 1. **Difficult Diagnosis and Time Delay**: - The study found that the time span from the onset of symptoms to diagnosis ranged from 1 month to 36 years, with an average time of 4.32 years and a median of 2 years. This indicates that the diagnosis process for these patients is very long and complex. 2. **Lack of Commercial Treatment Paths**: - Due to the very small patient population, the traditional drug development and commercialization paths cannot meet the needs of these patients. Therefore, the n - Lorem Foundation is committed to providing personalized treatment plans for these patients through ASO technology. 3. **Exploration of the Relationship between Genotype and Phenotype**: - The paper revealed the complex relationship between different gene mutations and their clinical symptoms through detailed genotype and phenotype analysis of 173 patients with extremely rare pathogenic mutations. For example, different variants of certain genes such as GNAL1, H3F3A, GBE1, UBTF, and PACS1 can lead to different phenotypic manifestations, even within the same gene. 4. **Feasibility of Personalized ASO Treatment**: - The study showed how to design and develop personalized ASO treatment plans according to the specific gene mutations of each patient and evaluate their efficacy through non - clinical and clinical data. The paper described in detail the specific cases of three patients affecting the central nervous system, eyes, and kidneys respectively, demonstrating the application of ASO treatment in different organs. ### Methods and Techniques - **ASO Design and Screening**: The research team used a variety of chemically modified ASOs (such as PS 2′ - MOE, GalNAc, cEt, etc.) and ensured their safety and effectiveness through a series of strict screening steps. - **Pre - clinical and Clinical Evaluation**: To ensure the safety and effectiveness of ASO, the research team developed a detailed pre - clinical and clinical evaluation process, including dose selection, administration route, and long - term safety monitoring. - **Personalized Treatment Process**: From the patient's application to the final treatment, the entire process needs to go through multiple stages of evaluation and optimization to ensure that each patient can obtain the most suitable treatment plan for them. In general, this paper aims to provide new hope and treatment options for patients with extremely rare genetic diseases by combining advanced genomics techniques and ASO therapy.

Genotypic and phenotypic analysis of 173 patients with extremely rare pathogenic mutations who applied for experimental antisense oligonucleotide treatment

Consensus guidelines for eligibility assessment of pathogenic variants to antisense oligonucleotide treatments

Preparing n-of-1 Antisense Oligonucleotide Treatments for Rare Neurological Diseases in Europe: Genetic, Regulatory, and Ethical Perspectives

Practical Recommendations for the Selection of Patients for Individualized Splice-Switching ASO-Based Treatments

A framework for individualized splice-switching oligonucleotide therapy

Preparing for Patient-Customized N-of-1 Antisense Oligonucleotide Therapy to Treat Rare Diseases

Joining forces to develop individualized antisense oligonucleotides for patients with brain or eye diseases: the example of the Dutch Center for RNA Therapeutics

Developing antisense oligonucleotides for a TECPR2 mutation-induced, ultra-rare neurological disorder using patient-derived cellular models

Advancing ASO therapies from development to implementation

Quantifying and mitigating motor phenotypes induced by antisense oligonucleotides in the central nervous system

Antisense oligonucleotides: a novel Frontier in pharmacological strategy

Therapeutic Antisense Oligonucleotides Are Coming of Age

Antisense Oligonucleotide Therapy for Neurodevelopmental Disorders

The application of antisense oligonucleotides in disease treatment

Antisense oligonucleotides and their applications in rare neurological diseases

Suppression of mutant C9orf72 expression by a potent mixed backbone antisense oligonucleotide

A Road to Cure in Light and Shade

Special Section on Pharmacokinetics and ADME of Biological Therapeutics — Minireview Absorption, Distribution, Metabolism, and Excretion of US Food and Drug Administration – Approved Antisense Oligonucleotide Drugs

Moving away from one disease at a time: Screening, trial design, and regulatory implications of novel platform technologies

Mechanisms of Action of the US Food and Drug Administration-Approved Antisense Oligonucleotide Drugs

Unveiling the potential of antisense oligonucleotides: Mechanisms, therapies, and safety insights